Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic le
Takeda has a chance of breaking into new territory with its blood cancer therapy Iclusig, after the drug performed better than mainstay therapy imatinib in a phase 3 study of adults with ne
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl